TECHWIRE 30
(CIX: WRAL30)  1,107.33  up arrow+2.45  (0.22 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: Apple)  101.00  up arrow+0.89  (0.88 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NY: QUINTILES)  56.05  down arrow-1.15  (-2.01 %)  Updated: 01:35 PM EDT, Sep 30 2014
(OP: BASF SE)  91.51  down arrow-0.28  (-0.3 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: BioCryst)  9.96  down arrow-0.53  (-5.05 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: BioDelivery)  17.33  down arrow-0.27  (-1.53 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: CEMP)  10.99  up arrow+0.19  (1.76 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: Cisco Systems)  25.15  up arrow+0.03  (0.12 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: Cree)  40.99  down arrow-0.43  (-1.03 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: DARA)  1.06  up arrow+0.01  (0.95 %)  Updated: 01:31 PM EDT, Sep 30 2014
(NY: EMC CORPORATION)  29.31  up arrow+0.48  (1.66 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: Extreme Networks)  4.79  up arrow+0.07  (1.48 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: FB)  79.14  up arrow+0.14  (0.17 %)  Updated: 01:36 PM EDT, Sep 30 2014
(NY: GLAXOSMITHKLINE)  46.06  down arrow-0.23  (-0.49 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: GOOG)  575.10  down arrow-1.26  (-0.22 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NY: IBM)  189.94  up arrow+0.3  (0.16 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NY: LH)  102.22  down arrow-0.92  (-0.89 %)  Updated: 01:35 PM EDT, Sep 30 2014
(OP: Lenovo Group)  29.61  down arrow-0.22  (-0.73 %)  Updated: 01:08 PM EDT, Sep 30 2014
(NY: MRK)  59.69  up arrow+0.28  (0.47 %)  Updated: 01:36 PM EDT, Sep 30 2014
(NQ: Microsoft Corp)  46.25  down arrow-0.19  (-0.41 %)  Updated: 01:36 PM EDT, Sep 30 2014
(NQ: NTAP)  42.89  up arrow+0.45  (1.06 %)  Updated: 01:36 PM EDT, Sep 30 2014
(NY: NOVARTIS AG)  94.11  up arrow+0.55  (0.59 %)  Updated: 01:35 PM EDT, Sep 30 2014
(OP: Novozymes A/S)  43.32  down arrow-0.47  (-1.07 %)  Updated: 01:25 PM EDT, Sep 30 2014
(NY: PFIZER)  29.70  down arrow-0.07  (-0.24 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: Pozen)  7.32  down arrow-0.3  (-3.88 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NY: RED HAT)  56.10  up arrow+0.61  (1.1 %)  Updated: 01:36 PM EDT, Sep 30 2014
(NQ: BBRY)  10.01  down arrow-0.22  (-2.15 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: Salix)  157.31  up arrow+1.53  (0.98 %)  Updated: 01:35 PM EDT, Sep 30 2014
(NQ: SQI)  15.01  down arrow-0.21  (-1.38 %)  Updated: 01:32 PM EDT, Sep 30 2014

Posts tagged “Genomics”

Updated August 15

Premium Lock Ebola outbreak brings global attention to tobacco plant-based drugs

It's an eye-catching angle in the story of an experimental treatment for Ebola: The drug comes from tobacco plants that were turned into living pharmaceutical factories. And one of the emerging players is Medicago, which operates a production facility in RTP.

How Medicago process works How Medicago process works

August 12

Premium Lock Pfizer, 23andMe team up for genetic study of bowel disease

DNA    Pfizer is teaming up with DNA testing company 23andMe to study the possible genetic underpinnings of inflammatory bowel disease, a hard-to-treat ailment that affects an estimated 1.4 million Americans.

Updated July 14

Premium Lock N.C. Research Campus internship program plants seeds to grow STEM careers

The future of food research is taking root in some very fertile ground - the minds of students working on the N.C. Research Campus. In an Insider exclusive for WRAL TechWire, read how a new internship program encourages STEM careers

Michael Balloskis, left, and Brooklyn Phillips in the P2EP program. Michael Balloskis, left, and Brooklyn Phillips in the P2EP program.

Updated June 24

Premium Lock New Jersey firm buying Gentris for $4.75M; founder to return

Morrisville-based Gentris, which provides storage and testing services to research laboratories, has received a $4.75 million buy-out offer from New Jersey-based Cancer Genetics,

Gentris Gentris

May 13

Premium Lock GSK to utilize genomics data, services from Metabolon

Triangle-based Metabolon, which recently struck a deal with DNA pioneer Craig Venter to help us find ways to live longer, has another high-profile partner: GlaxoSmithKline. The two neighbors disclosed a new collaboration agreement Tuesday.

Metabolon’s “Analytical Platform”: Metabolon’s “Analytical Platform”:

April 2

Premium Lock Drug giant Baxter acquires Chapel Hill firm for $70M

Heart research Baxter International is acquiring Chapel Hill-based Chatham Therapeutics to gain control of gene-based therapy technology focused on hemophilia. The deal includes a $70 million upfront payment. Additional payments could be made based on development, regulatory and commercial milestones.

Updated March 29

Premium Lock On Human Genome Project anniversary, NHGRI's Green sees Big Data bottlenecks ahead

Eric Green National Human Genome Research Institute Director Eric Green recognizes the progress made since the first human genome was sequenced 10 years ago. Read about the Big Data challenges he sees ahead.

Updated March 28

Premium Lock Vivek Wadhwa: A story about the $32,000 startup sold for millions

Vivek Wadhwa I meet entrepreneurs all over the world who think that venture capital is a prerequisite for starting a company. They write business plans and ask for introductions to venture capitalists. I tell them that they should instead bootstrap their startups; that what would have cost millions of dollars a few years ago now costs thousands. This story is about one startup that bootstrapped, rebooted and sold for millions.

Updated March 19

Premium Lock Vivek Wadhwa: Humans have become software; amazing advances lie ahead

Vivek Wadhwa Opinion: Hardly a week goes by without the announcement of a major scientific breakthrough in genomics. This means that medicine will, within a few years, start advancing at the same pace as the Internet and software. And, we will see a revolution in health care.

Updated March 6

Premium Lock Genome pioneer Craig Venter launches DNA firm aiming to help us all live to be 100

J. Craig Venter, the man who raced the U.S. government to sequence the first human genome, has a new goal: Help everyone live to 100, in good health. And one of his first partners is RTP-based Metabolon, where he serves as a scientific adviser.

A sample of testing done at Craig Venter's new firm A sample of testing done at Craig Venter's new firm

Updated March 6

Premium Lock RTP's Metabolon to help genome pioneer Craig Venter find ways to help us live longer

Metabolon will utilize its proprietary molecular technology to help Human Longevity Inc., the new company led by genome pioneer Craig Venter, to find indications of disease and gene mutations.

Mapping the genome Mapping the genome

Updated August 13, 2013

Premium Lock $5.3M grant to fund expansion of RTI genomic testing tools

A grant from the National Human Genome Research Institute will enable RTI International to enhance genomic research through its no-cost PhenX Toolkit.

PhenX Toolkit PhenX Toolkit

August 2, 2013

Premium Lock N.C. Biotech Center celebrates investment trifecta

The N.C. Biotech Center notes recent wins of three Triangle life science firms whose start included support from the Biotech Center

Heat Biologics IPO Heat Biologics IPO

February 25, 2013

Premium Lock CED panel to explore how healthcare changes affect medtech companies

Analysis: At the CED Life Science Conference 2013, we will address the changes, challenges and opportunities in the medical device industry and study working models of successful medtech businesses.

CED Life Science conference CED Life Science conference

December 5, 2012

Premium Lock RTP genomics firm Metabolon lands deal renewal with Syngenta

New crop research facility coming to N.C. Metabolon and Syngenta have renewed an agreement through which Metabolon provides biochemical profiling technology to the agribusiness giant.

Updated October 22, 2012

Premium Lock State of life science in N.C.: 'Highs' mixed with 'lows'

Biotech & Life Science Throughout a day-long program, business leaders reflect on the "highs" wrought by the unique collaborative environment permeating North Carolina's life-science community, to the "lows" of an uncertain global economic and regulatory climate.

Updated August 13, 2012

Premium Lock Quintiles acquires RTP-based genomics testing firm

The deal advances Quntiles' efforts to advance personalized medicine, the company says. Expression Analysis recently won a $27 million contract with the EPA.

EA now part of Quintiles EA now part of Quintiles

Updated August 1, 2012

Premium Lock RTP genomics firm Metabolon buys California company

Metabolon Metabolon adds lipids capabilities in deal for Lipomics Technologies. Its top executive becomes CTO at Metabolon.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll